ReviewMolecular biotechnology2026
Applications of Recombinant DNA Technology in Medicine: A Comprehensive Review.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant DNA (rDNA) technology has revolutionised modern medicine by providing precise genetic manipulation for therapeutic, diagnostic, and preventive uses. By integrating genetic material from multiple sources, rDNA permits the creation of physiologically active compounds and the development of new medical therapies. This study summarises the basics of rDNA technology, including DNA separation, gene cloning, vector design, transformation, and expression systems, emphasising their foundational importance in biotechnology. Recombinant procedures make it possible to produce insulin, growth hormones, interferons, monoclonal antibodies, and enzymes on a large scale with better purity, safety, and scalability in the biopharmaceutical industry. Subunit, DNA, and viral-vector vaccines are examples of recombinant vaccines that have been effectively used to prevent infectious diseases such COVID-19, HPV, and hepatitis B. Gene therapy techniques using viral and non-viral vectors, together with CRISPR-based genome editing, provide targeted repair of genetic diseases. Additionally, recombinant systems promote pharmacogenomics and personalised medicine by improving molecular diagnostics such as PCR, qPCR, DNA probes, and enzyme-based tests. Furthermore, platforms for translational research and disease modelling are provided by genetically modified animal and cell models. The paper further examines ethical, safety, and regulatory considerations, as well as upcoming technologies such as CRISPR 2.0, synthetic biology, mRNA therapies, and designer vaccinations. Together, rDNA technology is still revolutionising healthcare by providing novel approaches to illness diagnosis, treatment, and prevention.
Indexed as
Identifiers
42402538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.